Enjoy complimentary customisation on priority with our Enterprise License!
The regenerative medicine market is projected to reach a value of USD 70.11 billion, accelerating at a CAGR of 23.31% between 2023 and 2028. The escalating prevalence of chronic diseases serves as a pivotal catalyst for the burgeoning growth of various markets. As chronic conditions continue to afflict a significant portion of the global population, there is an increasing demand for innovative solutions and treatments to address these health challenges.
For More Highlights About this Report, Download Free Sample in a Minute
The market is a dynamic landscape encompassing various domains such as blood cancers, rare diseases, and chronic genetic disorders. Notably, advancements in personalized medicine, gene therapy, and CRISPR therapy are driving transformative changes. Companies like Metcela Inc, Integra LifeSciences, and ACell, Inc are pivotal players in this sector, leveraging their R&D capabilities to develop innovative cellular therapies and tissue engineering solutions. Strategic initiatives such as mergers, research collaborations, and partnerships are fostering the development of groundbreaking treatments like CAR-T treatment and gene therapy. Moreover, the focus on platelet-rich plasma and advancements in orthopedics and wound care underscore the market's potential in oncology and tissue regeneration. This market segmentation showcases a thriving ecosystem propelled by healthcare expenditure, government organizations' support, and a robust pipeline of innovative pipeline candidates across various therapeutic areas.
The market share growth by the oncology segment will be significant during the forecast period. The global regenerative medicines market is poised for significant growth in the oncology application segment during the forecast period. Government data from organizations such as the World Health Organization (WHO) and the European Medicines Agency (EMA) indicate that a number of variables contribute to this trend.
Get a glance at the market contribution of various segments Download the PDF Sample
The oncology segment was the largest and was valued at USD 5.58 billion in 2018. Regenerative medicine offers cutting-edge cellular therapies such as CAR-T cell therapy and stem cell-based therapeutics. These discoveries have the potential to treat a number of malignancies, including leukemia and lymphoma. Also, Governments are supporting the development of regenerative medicine through regulatory assistance. The market in focus is expanding due to EMA rules on advanced treatment medical products (ATMPs). Governments are supporting the development of regenerative medicine through regulatory assistance. The market in focus is expanding due to EMA rules on advanced treatment medical products (ATMPs). Such factors are expected to fuel the growth of the segment which in turn drives the market growth during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 48% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
In North America, approximately 510 regenerative medicine companies operate, with leading players such as Integra LifeSciences, MiMedx, Organogenesis, and Zimmer Biomet Holdings Inc. spearheading regional market growth. These entities are actively introducing novel products and restructuring sales strategies to enhance their market presence. Various factors, including the rising incidence of chronic and acute diseases, a rapidly aging populace, heightened awareness of regenerative therapies, widespread acceptance of cell and tissue-based therapies and gene therapy, the substantial presence of tissue banks, and a concerted emphasis on regenerative medicine, collectively drive market expansion across the region. In Canada, robust demand for superior medical technologies, escalating healthcare expenditure, and institutional backing, notably from the Centre for Commercialization of Regenerative Medicine, are fostering the adoption of regenerative medicine and bolstering market growth..
The landscape of healthcare is rapidly evolving with advancements in personalized medicine, gene therapy, and CRISPR therapy revolutionizing treatments for blood cancers, rare diseases, and chronic genetic disorders. Innovative pipeline candidates in oncology, cellular therapies, and gene therapy hold promise for improved patient outcomes. As healthcare expenditure rises, research grants fuel R&D capabilities, driving discoveries like the TRIM72 protein's role in vasculature and skeletal muscles. Companies like Integra LifeSciences lead in orthopedics and wound care, while CellPoint pioneers cellular therapies like CAR-T treatment and tissue engineering. Platelet-rich plasma offers novel solutions, underscoring the dynamic intersection of science and patient care.
The rising incidence of chronic diseases is a key driver of market growth. Globally, there is a growing prevalence of conditions like heart disease, diabetes, stroke, cancer, obesity, and arthritis, posing a substantial burden on both patients and healthcare systems.
Moreover, in the US, a significant portion of the population contends with one or more chronic health conditions, with one in four adults facing two or more chronic diseases. Unhealthy lifestyle habits, including insufficient exercise, poor nutrition, and substance abuse (such as alcohol and tobacco addiction), contribute significantly to the risk factors associated with chronic diseases.
The rising significance of Chimeric Antigen Receptor T-cell (CAR-T) therapies is a notable trend influencing market growth. CAR-T therapies, a key development in the global market, demonstrate the potential of genetically modifying a patient's T-cells to target and eliminate cancer cells, particularly in hematological malignancies like leukemia and lymphoma. FDA-approved CAR-T treatments, such as Kymriah and Yescarta, have shown remarkable success in treating large B-cell lymphoma and refractory B-cell acute lymphoblastic leukemia (ALL).
Furthermore, the established precedent of regenerative medicine in other disease areas enhances the market's growth potential. The ability to engineer a patient's immune cells for personalized, targeted cancer treatments is expected to drive the global market in the forecast period.
The increasing complexity of regenerative medicine products poses a significant challenge to market growth. These products, including those categorized as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) for cell therapy, exhibit complexity in various aspects, such as donor and tissue sources, product characterization, mechanism of action, potency, efficacy, and safety.
Furthermore, procedures involving the extraction and manipulation of an individual's cells for regenerative medicine, notably ex vivo autologous therapies, entail intricate processes and necessitate diverse procedures and care settings. This complexity poses challenges for healthcare systems originally tailored for conventional therapies. Additionally, there exists an insufficient regulatory framework and lack of reimbursement for such intricate therapies. Consequently, the slow adoption rate of highly complex regenerative products is expected, presenting a barrier to market growth in the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers regenerative medicine solutions such as Alloderm select and Alloderm.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
The market growth and forecasting analysis of companies involves both qualitative and quantitative assessments to provide clients with insights into the broader business landscape and the strengths and weaknesses of key market players. Qualitative analysis categorizes companies based on their focus as pure play, category-focused, industry-focused, or diversified. On the other hand, quantitative analysis categorizes companies according to their market position as dominant, leading, strong, tentative, or weak. This comprehensive approach aids in understanding market dynamics and assists clients in making informed decisions regarding their business strategies.
The market is at the forefront of medical innovation, targeting various conditions like blood cancers, rare diseases, and chronic genetic disorders. Advancements in personalized medicine and CRISPR therapy have revolutionized treatment approaches, particularly through CAR-T treatment and investigational CAR-T cell therapies. Companies like Metcela Inc are leveraging their R&D capabilities to develop biological therapies and Molecular medicines, especially for conditions like diabetes type 1 & 2 and neurodegenerative diseases such as Alzheimer’s. This market's growth is propelled by strategic acquisitions, research grants, and government organizations' initiatives, including FDA regulatory approvals and RMAT designation for breakthrough therapies.
Moreover, the focus on tissue engineering, stem cell regeneration, and cell regeneration therapy indicates a shift towards regenerative knee treatment and tissue repair and replacement. Challenges persist in orthopedic challenges and traditional surgeries, prompting interest in Nanotechnology and regenerative therapy for musculoskeletal treatments and spinal cord injuries. As regenerative medicine continues to evolve, it holds promise for addressing age-related disorders and reducing the prevalence of cancer and cancer-related deaths while advancing cardiovascular segment with cell-based therapies.
Market Scope |
|
Report Coverage |
Details |
Page number |
178 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 23.31% |
Market growth 2024-2028 |
USD 70.11 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
22.43 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 48% |
Key countries |
US, Germany, UK, Japan, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., Baxter International Inc., Becton Dickinson and Co., Cook Group Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Integra Lifesciences Corp., Johnson and Johnson, Medtronic Plc, Merck and Co. Inc., Mesoblast Ltd., MiMedx Group Inc., Novartis AG, Nuvasive Inc., Organogenesis Holdings Inc., Smith and Nephew plc, Thermo Fisher Scientific Inc., Vericel Corp., and Zimmer Biomet Holdings Inc. |
Market dynamics |
Parent market analysis, market growth analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.